FDA grants Vitrase 5 years' exclusivity

The FDA has extended ISTA Pharmaceuticals' market exclusivity for hyaluronidase for injection (Vitrase) to 5 years from 3 years. The exclusivity will end May 5, 2009.

Related Videos
Related Content

Pinpointing neurologic dysfunction in fundus photographs using deep learning analysis

March 26th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Alzheimer’s disease changes may be reflected in the eyes first

March 24th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Ophthalmology practice agrees to pay more than $2.9 million to settle kickback allegations

March 24th 2023

Study examines frequency of retinopathy in patients diagnosed with type 2 diabetes mellitus

March 24th 2023

Pinpointing neurologic dysfunction in fundus photographs using deep learning analysis

March 26th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Alzheimer’s disease changes may be reflected in the eyes first

March 24th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Ophthalmology practice agrees to pay more than $2.9 million to settle kickback allegations

March 24th 2023

Study examines frequency of retinopathy in patients diagnosed with type 2 diabetes mellitus

March 24th 2023

Pinpointing neurologic dysfunction in fundus photographs using deep learning analysis

March 26th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Alzheimer’s disease changes may be reflected in the eyes first

March 24th 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Ophthalmology practice agrees to pay more than $2.9 million to settle kickback allegations

March 24th 2023

Study examines frequency of retinopathy in patients diagnosed with type 2 diabetes mellitus

March 24th 2023
© 2023 MJH Life Sciences

All rights reserved.